Table 1 Key baseline characteristics before vaccination

From: A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma

Patient no.

Age

Sex

ECOG a

Risk factor

LC b

HCC stage

Treatment records before DC vaccination

ChildPugh score

AFP (ng ml-1)

PIVKA-II (nAU ml−1)

01

63

F

0

HBV

Yes

I

R

5

18.3

13

02

61

M

0

HBV

Yes

I

R

5

7.1

19

03

53

M

0

HBV

Yes

I

R

5

6.1

19

04

53

M

0

HBV

Yes

II

T/T/R/T

5

7.0

14

05

45

M

0

HBV

Yes

I

P/P/Op

5

5.4

16

06

50

M

0

HBV

Yes

II

T/P/P/P

5

6.5

18

07

60

M

0

HBV

Yes

I

P/T/R

6

3.3

27

08

66

M

0

U/N

Yes

I

Op

5

2.9

21

09

52

M

0

HBV

Yes

IIIA

T/T/T/T/T

5

5470.0

2040

10

57

M

0

HBV

No

IIIA

Op

5

2.6

30

11

57

F

0

HBV

Yes

I

Op

5

6.6

9

12

71

M

0

Alcohol

Yes

I

T/T/T/T/T/P

6

12.0

18

  1. *Abbreviations: AFP=alpha-fetoprotein; ECOG=Eastern Cooperative Oncology Group; HBV=hepatitis B virus; HCC=hepatocellular carcinoma; LC=liver cirrhosis; O=operation (resection); P(PEI)=percutaneous ethanol injection; PIVKA-II=protein induced by vitamin K absence-II; R(RFA)=radiofrequency ablation; T (TACE)=transarterial chemoembolization.
  2. aThe ECOG performance status assesses the daily living abilities of the patient, on a scale ranging from 0 (fully active) to 5 (dead).
  3. bLiver cirrhosis (LC) was diagnosed by the presence of histological and radiological evidence.
Back to article page